The high incidence of germline BRCA1 and BRCA2 mutations in ovarian cancer, has suggested that genetic assessment of women with ovarian cancer especially those with nonmucinous high-grade serous histology, will improve mutation carrier detection rates [14,18]. This evidence concerns the gene BRCA2 and ovarian carcinoma.